EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma

Toshiki Kijima iD, Atsuko Takada-Owada, Hiroki Shimoda, Hidetoshi Kokubun, Toshitaka Uematsu, Kohei Takei, Hironori Betsunoh, Masahiro Yashi, Kazuyuki Ishida, Takao Kamai iD

BJUI Compass · 2025-01 · 6 (1)

DOI: 10.1002/bco2.488 ↗

At a glance

Journal article in BJUI Compass, published online on 2025-01-11. Written by Toshiki Kijima and 9 co-authors. Institution: Department of Urology Dokkyo Medical University Tochigi Japan. Cited 8 times so far (Crossref); 17 references. The full text is freely available (open access, CC BY 4.0). Funded by: Japan Society for the Promotion of Science.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Objective

To evaluate the correlation between ATP‐binding cassette (ABC) transporter expression and therapeutic efficacy of enfortumab vedotin (EV), an antibody‐drug conjugate targeting Nectin‐4, in urothelial cancer, as only a few studies have been conducted on this topic. Patients and methods This retrospective study included 20 patients with metastatic urothelial carcinoma (mUC), including bladder and upper urinary tract cancers, who were treated with EV at Dokkyo Medical University Hospital between 2022 and 2024. Immunohistochemical staining was performed on formalin‐fixed, paraffin‐embedded tissue samples. Progression‐free survival (PFS) was estimated using the Kaplan–Meier method, and differences between subgroups (e.g., Nectin‐4 and ABC transporter expression) were compared using the log‐rank test.

Results

Immunohistochemical analysis indicated that tumours with high ABC transporter expression exhibited shorter PFS time and poorer response to EV. Furthermore, a decrease in Nectin‐4 expression and an increase in ABC transporter expression were observed as the disease progressed from non‐muscle‐invasive to muscle‐invasive and metastatic. Patients with Nectin‐4‐positive and ABC transporter‐negative tumours had the longest PFS, underscoring the prognostic significance of these biomarkers.

Conclusion

To our knowledge, this study is the first to show a correlation between ABC transporter expression and EV efficacy in urothelial carcinoma. Future research should focus on optimizing treatment strategies based on Nectin‐4 and ABC transporter expression to improve outcomes.

Subjects

Author keywords

ABC transportersEnfortumab VedotinNectin‐4drug resistancemetastatic urothelial carcinoma

Authors and institutions

  • Department of Urology Dokkyo Medical University Tochigi Japan.
  • Department of Diagnostic Pathology Dokkyo Medical University Tochigi Japan.
  • Department of Urology Tokyo Medical and Dental University, Dokkyo Medical University Tokyo Japan.

ORCID profiles: Toshiki Kijima, Takao Kamai

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Kijima, T., Takada-Owada, A., Shimoda, H., Kokubun, H., Uematsu, T., Takei, K., Betsunoh, H., Yashi, M., Ishida, K., & Kamai, T. (2025). Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma. BJUI Compass, 6(1). https://doi.org/10.1002/bco2.488

Vancouver

Kijima T, Takada-Owada A, Shimoda H, Kokubun H, Uematsu T, Takei K, et al. Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma. BJUI Compass. 2025;6(1). doi:10.1002/bco2.488

BibTeX
@article{Kijima2025,
  author = {Kijima, Toshiki and Takada-Owada, Atsuko and Shimoda, Hiroki and Kokubun, Hidetoshi and Uematsu, Toshitaka and Takei, Kohei and Betsunoh, Hironori and Yashi, Masahiro and Ishida, Kazuyuki and Kamai, Takao},
  title = {Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma},
  journal = {BJUI Compass},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1002/bco2.488}
}
Start for free →